Literature DB >> 3011627

Calcitonin induced increase in ACTH, beta-endorphin and cortisol secretion.

L Laurian, Z Oberman, E Graf, S Gilad, E Hoerer, R Simantov.   

Abstract

The response of ACTH, beta-endorphin and cortisol to calcitonin administration was investigated in 8 subjects with recent fractures of the vertebrae due to postmenopausal or senile osteoporosis (Ost) and in seven normal healthy controls (NC). A significant increase of the three hormones was observed in 13 subjects. The maximum increase was observed between 15 and 60 min.: the cortisol level (microgram/100 ml) rose from 14.3 +/- 1.9 to 24.8 +/- 3.2 (P less than 0.05) in Ost and from 7.7 +/- 0.6 to 21.7 +/- 1.7 (P less than 0.001) in NC, the beta-endorphin (pmol/l) from 5.8 +/- 0.6 and to 21.2 +/- 1.3 in OST (P less than 0.001) and from 5.9 +/- 0.4 to 21.9 +/- 4.5 (P less than 0.01) in NC and the ACTH levels (pg/ml) from 21.3 +/- 5.7 to 61.7 +/- 3.6 (P less than 0.001) in OST and from 30.0 +/- 6.2 to 58.8 +/- 7.5 (P less than 0.05) in NC. The results indicate a possible role of calcitonin in modulating the anterior pituitary function. It also suggests that the analgesic effect of calcitonin might be mediated by the increase of beta-endorphin. The possibility that this analgesic effect of calcitonin is due to its direct binding to the opiate receptors was excluded in the present study by in vitro binding assay.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3011627     DOI: 10.1055/s-2007-1012291

Source DB:  PubMed          Journal:  Horm Metab Res        ISSN: 0018-5043            Impact factor:   2.936


  20 in total

1.  Mechanisms for ovariectomy-induced hyperalgesia and its relief by calcitonin: participation of 5-HT1A-like receptor on C-afferent terminals in substantia gelatinosa of the rat spinal cord.

Authors:  A Ito; E Kumamoto; M Takeda; K Shibata; H Sagai; M Yoshimura
Journal:  J Neurosci       Date:  2000-08-15       Impact factor: 6.167

Review 2.  Intranasal salcatonin (salmon calcitonin). A review of its pharmacological properties and role in the management of postmenopausal osteoporosis.

Authors:  G L Plosker; D McTavish
Journal:  Drugs Aging       Date:  1996-05       Impact factor: 3.923

3.  Intranasal calcitonin for the prevention of bone erosion and bone loss in rheumatoid arthritis.

Authors:  A Sileghem; P Geusens; J Dequeker
Journal:  Ann Rheum Dis       Date:  1992-06       Impact factor: 19.103

Review 4.  Use of calcitonin in the treatment of bone pain associated with osteoporosis.

Authors:  C Gennari; D Agnusdei; A Camporeale
Journal:  Calcif Tissue Int       Date:  1991       Impact factor: 4.333

Review 5.  Salmon calcitonin: a review of current and future therapeutic indications.

Authors:  C H Chesnut; M Azria; S Silverman; M Engelhardt; M Olson; L Mindeholm
Journal:  Osteoporos Int       Date:  2007-12-11       Impact factor: 4.507

6.  Increase of pain threshold by calcitonin during electrical stimulation of the dental pulp. Investigations in healthy volunteers with regard to plasma concentration.

Authors:  K Welzel; D Welzel
Journal:  Schmerz       Date:  1989-09       Impact factor: 1.107

7.  Additive effect of elcatonin to risedronate for chronic back pain and quality of life in postmenopausal women with osteoporosis: a randomized controlled trial.

Authors:  Michio Hongo; Naohisa Miyakoshi; Yuji Kasukawa; Yoshinori Ishikawa; Yoichi Shimada
Journal:  J Bone Miner Metab       Date:  2014-08-15       Impact factor: 2.626

8.  Effects of calcitonin on human auditory and visual evoked brain potentials.

Authors:  R Pietrowsky; M Dentler; H L Fehm; J Born
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

9.  Plasma beta-endorphin, ACTH and cortisol secretion in man after nasal spray administration of calcitonin.

Authors:  R Franceschini; A Cataldi; T Barreca; M Salvemini; E Rolandi
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

Review 10.  Future horizons for calcitonin: a U.S. perspective.

Authors:  J H Carstens; J D Feinblatt
Journal:  Calcif Tissue Int       Date:  1991       Impact factor: 4.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.